nytimes.com / .nytimes-com-health / Page 7

The attacks came out of nowhere and brought life to a miserable standstill. And she had the scars to prove it.

President-elect Donald J. Trump's selections to run the nation's health agencies are alarming infectious disease experts.

Robert F. Kennedy Jr. and other candidates for top health posts are at odds with the drug industry, setting the stage for tense battles over regulatory changes.

Talking about your advance care directive with your loved ones will make life -- and death -- easier later on.

When it comes to weeding out corporate influence, Robert F. Kennedy Jr.'s ideas often align best with some of Trump's loudest critics.

As the director of the National Institutes of Health, Dr. Jay Bhattacharya would oversee the world's premier medical research agency, with a $47 billion budget and 27 separate institutes and centers.

The drug, which is named MariTide and delivered in a monthly injection, is years from being sold, but caused an average of up to 20 percent weight loss in a small group of patients.

And it's on the rise among middle-aged drinkers.

The proposed rule could give millions of Americans access to the new drugs; it would also put pressure on the federal budget.

Researchers are trying to understand why resistant pathogens are so prevalent in the war-torn nations of the Middle East.